IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the Company will redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), that were issued under the Warrant Agreement, dated February 8, 2021 (the “Warrant Agreement”), by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent (the “Warrant Agent”), as part of the units sold in the Company’s initial public offering (the “IPO”), for a redemption price of $0.10 per Public Warrant (the “Redemption Price”), that remain outstanding at 5:00 p.m. New York City time on… 

Die Entwicklung der künstlichen Intelligenz (KI) hat die Arbeitskultur auf der ganzen Welt erheblich beeinflusst. KI hat Unternehmen dazu veranlasst, eine Vier-Tage-Woche einzuführen und ihren Mitarbeitern mehr Remote-Positionen anzubieten. Nach Angaben des Office for National Statistics waren im vergangenen Jahr derzeit 44 Prozent der britischen Arbeitnehmer in Positionen beschäftigt, die Remote-Kapazität bieten. Will Ahmed, der […] Dieses 3,6 Milliarden US-Dollar teure Gesundheitstechnologie-Start-up aus Boston zahlt seinen Mitarbeitern mehr Schlaf

Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The treatment resulted in an acceptable safety profile, with no observed clinical signs of early neurotoxicity, warranting larger clinical studies in subjects with multiple sclerosis https://www.cell.com/med/fulltext/S2666-6340(24)00114-4

BOSTON, March 29, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2023, and provided recent business highlights. Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

– Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in combination with anti-PD-1 – Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) — Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024. Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) — Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024. Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Eine vom Bundesverkehrsministerium eingesetzte unabhängige Expertengruppe empfiehlt, dass der THC-Grenzwert im Straßenverkehr künftig bei 3,5 Nanogramm pro Milliliter Blutserum liegen soll. Das teilte das Ministerium am Donnerstag mit. Bei Erreichen dieses THC-Grenzwertes sei nach dem aktuellen Stand der Wissenschaft eine verkehrssicherheitsrelevante Wirkung beim Führen eines Kraftfahrzeuges „nicht fernliegend“, aber „deutlich unterhalb der Schwelle“, ab der […] Expertengruppe legt Ergebnis zu THC-Grenzwert im Straßenverkehr vor

Der Bundesrechnungshof hat scharfe Kritik an der Maskenbeschaffung in der Coronakrise unter Bundesgesundheitsminister Jens Spahn (CDU) geübt und dessen Haus eine mangelnde Aufarbeitung vorgeworfen. „Die massive Überbeschaffung von Schutzmasken zu Beginn der Coronapandemie durch das Bundesministerium für Gesundheit (BMG) führte zu anhaltend hohen Lagerbeständen und erheblichen Folgekosten“, heißt es in einem Bericht des Bundesrechnungshofs an […] Rechnungshof kritisiert Spahns Maskenbeschaffung massiv

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates